INS and cancer: By reducing the concentration of insulin and IGF-1, metformin not only decreases the downstream signaling pathways of these receptors in cancer cells but also downregulates other molecules that promote tumor growth, including growth factors, sex hormones, proinflammatory cells, cytokines, and metabolic intermediates.